Neutralizes the SARS-CoV-2 Omicron Variant
- During in vitro pseudovirus assays, IPA's PolyTope® advanced immunotherapeutic TATX-03 prevents infection of cells by SARS-CoV-2 variant-of-concern, Omicron, and all variants of concern tested to date.
- On January 27, 2022, Talem Therapeutic LLC, a wholly owned subsidiary of IPA, filed a non-provisional US patent application and concurrent PCT (Patent Cooperation Treaty) international and other national patent applications, relating to the discovery of PolyTope TATX-03, its in vitro and in vivo effects, and therapeutic use.
IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company”) (NASDAQ: IPA) (TSXV: IPA) is pleased to announce the release of data demonstrating strong neutralizing potency of its PolyTope® TATX-03 antibody cocktail towards the SARS-CoV-2 Omicron variant (B.1.1.529) in in vitro pseudovirus assays. This first generation four antibody cocktail against SARS-CoV-2 was rationally designed to sustain efficacy against all SARS-CoV-2 strains and variants with the goal of protecting and treating all individuals. The Company believes that it possesses the only first-generation cocktail therapy against SARS-CoV-2 (first publicly announced 2020) that has been demonstrated to retain efficacy against every variant of concern to date through in vitro pseudovirus assays conducted with respect to such variants of concern. PolyTope TATX-03 is unique in its ability to engage multiple modes of action, facilitated through simultaneously targeting various non-overlapping epitopes on the spike trimer.
https://www.businesswire.com/news/home/20220131005322/en/